First-in-man clinical study of SCMod1 [Modi-1 / AMPLIVANT combination] for cancer

Trial Profile

First-in-man clinical study of SCMod1 [Modi-1 / AMPLIVANT combination] for cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs SCMod1 (Primary)
  • Indications Breast cancer; Endometrial cancer; Osteosarcoma; Ovarian cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 03 Apr 2018 According to a Scancell media release, clinical studies are scheduled to start in H1 2019 .
    • 15 Feb 2018 According to an ISA Pharmaceuticals media release, the company has granted Scancell an exclusive worldwide license to manufacture, develop and commercialise the AMPLIVANT:Modi-1 conjugate therapy and expect to commence this trial in H1 2019.
    • 13 Sep 2017 According to a Scancell media release, the company is aiming to file a Clinical Trial Application (CTA) in the UK for the planned Phase 1/2 clinical trial in breast cancer, ovarian cancer and sarcoma in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top